---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-012514"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:17:13.871122+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics updates with strong LOTIS-7 combo data; ZYNLONTA expansion plans detailed

## Summary
- LOTIS-7 (ZYNLONTA+glofitamab) achieved 86.7% CR rate in r/r LBCL; 93.3% ORR in evaluable patients (N=30).
- LOTIS-5 Phase 3 trial fully enrolled; topline data expected 1H 2026 for potential sBLA submission.
- ZYNLONTA Phase 2 IIT in r/r MZL showed 69.2% CR and 84.6% ORR (N=26 evaluable); CR maintained in 17/18 patients.
- PSMA-targeting ADC progresses IND-enabling activities; seeking research collaborations.
- Cash runway expected into 2028; company continues to grow ZYNLONTA revenue.

## SEC filing metadata
- accession: 0000950103-25-012514
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000095010325012514/0000950103-25-012514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000095010325012514/dp235214_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-012514
- JSON: https://secwatch.observer/filing/0000950103-25-012514.json
- Plain text: https://secwatch.observer/filing/0000950103-25-012514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.